Anne M Fitzpatrick1, Susan T Stephenson2, Milton R Brown2, Khristopher Nguyen2, Shaneka Douglas2, Lou Ann S Brown3. 1. Department of Pediatrics, Emory University, Atlanta, Ga; Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, Ga. Electronic address: anne.fitzpatrick@emory.edu. 2. Department of Pediatrics, Emory University, Atlanta, Ga. 3. Department of Pediatrics, Emory University, Atlanta, Ga; Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, Ga.
Abstract
BACKGROUND: Severe asthma in children is a heterogeneous disorder associated with variable responses to corticosteroid treatment. Criterion standards for corticosteroid responsiveness assessment in children are lacking. OBJECTIVE: This study sought to characterize systemic corticosteroid responses in children with severe asthma after treatment with intramuscular triamcinolone and to identify phenotypic and molecular predictors of an intramuscular triamcinolone response. METHODS: Asthma-related quality of life, exhaled nitric oxide, blood eosinophils, lung function, and inflammatory cytokine and chemokine mRNA gene expression in peripheral blood mononuclear cells were assessed in 56 children with severe asthma at baseline and 14 days after intramuscular triamcinolone injection. The Asthma Control Questionnaire was used to classify children with severe asthma into corticosteroid response groups. RESULTS: Three groups of children with severe asthma were identified: controlled severe asthma, children who achieved control after triamcinolone, and children who did not achieve control. At baseline, these groups were phenotypically similar. After triamcinolone, discordance between symptoms, lung function, exhaled nitric oxide, and blood eosinophils was noted. Clinical phenotypic predictors were of limited utility in predicting the triamcinolone response, whereas systemic mRNA expression of inflammatory cytokines and chemokines related to IL-2, IL-10, and TNF signaling pathways, namely, AIMP1, CCR2, IL10RB, and IL5, strongly differentiated children who failed to achieve control with triamcinolone administration. CONCLUSIONS: Systemic corticosteroid responsiveness in children with severe asthma is heterogeneous. Alternative prediction models that include molecular endotypic as well as clinical phenotypic features are needed to identify which children derive the most clinical benefit from systemic corticosteroid step-up therapy given the potential side effects.
BACKGROUND: Severe asthma in children is a heterogeneous disorder associated with variable responses to corticosteroid treatment. Criterion standards for corticosteroid responsiveness assessment in children are lacking. OBJECTIVE: This study sought to characterize systemic corticosteroid responses in children with severe asthma after treatment with intramuscular triamcinolone and to identify phenotypic and molecular predictors of an intramuscular triamcinolone response. METHODS:Asthma-related quality of life, exhaled nitric oxide, blood eosinophils, lung function, and inflammatory cytokine and chemokine mRNA gene expression in peripheral blood mononuclear cells were assessed in 56 children with severe asthma at baseline and 14 days after intramuscular triamcinolone injection. The Asthma Control Questionnaire was used to classify children with severe asthma into corticosteroid response groups. RESULTS: Three groups of children with severe asthma were identified: controlled severe asthma, children who achieved control after triamcinolone, and children who did not achieve control. At baseline, these groups were phenotypically similar. After triamcinolone, discordance between symptoms, lung function, exhaled nitric oxide, and blood eosinophils was noted. Clinical phenotypic predictors were of limited utility in predicting the triamcinolone response, whereas systemic mRNA expression of inflammatory cytokines and chemokines related to IL-2, IL-10, and TNF signaling pathways, namely, AIMP1, CCR2, IL10RB, and IL5, strongly differentiated children who failed to achieve control with triamcinolone administration. CONCLUSIONS: Systemic corticosteroid responsiveness in children with severe asthma is heterogeneous. Alternative prediction models that include molecular endotypic as well as clinical phenotypic features are needed to identify which children derive the most clinical benefit from systemic corticosteroid step-up therapy given the potential side effects.
Authors: Anne M Fitzpatrick; Susan T Stephenson; Graham R Hadley; Leandrea Burwell; Madhuri Penugonda; Dawn M Simon; Jason Hansen; Dean P Jones; Lou Ann S Brown Journal: J Allergy Clin Immunol Date: 2011-04-22 Impact factor: 10.793
Authors: Anne M Fitzpatrick; Melinda Higgins; Fernando Holguin; Lou Ann S Brown; W Gerald Teague Journal: J Allergy Clin Immunol Date: 2010-04 Impact factor: 10.793
Authors: R G Ogirala; T M Sturm; T K Aldrich; F F Meller; E B Pacia; A M Keane; R I Finkel Journal: Am J Respir Crit Care Med Date: 1995-11 Impact factor: 21.405
Authors: George L Clemmer; Ann Chen Wu; Bernard Rosner; Michael J McGeachie; Augusto A Litonjua; Kelan G Tantisira; Scott T Weiss Journal: J Allergy Clin Immunol Date: 2015-05-05 Impact factor: 10.793
Authors: Atul Gupta; Sarah Dimeloe; David F Richards; Emma S Chambers; Cheryl Black; Zoe Urry; Kimuli Ryanna; Emmanuel Xystrakis; Andrew Bush; Sejal Saglani; Catherine M Hawrylowicz Journal: Thorax Date: 2013-12-17 Impact factor: 9.139
Authors: Anne M Fitzpatrick; Stanley J Szefler; David T Mauger; Brenda R Phillips; Loren C Denlinger; Wendy C Moore; Ronald L Sorkness; Sally E Wenzel; Peter J Gergen; Eugene R Bleecker; Mario Castro; Serpil C Erzurum; John V Fahy; Benjamin M Gaston; Elliot Israel; Bruce D Levy; Deborah A Meyers; W Gerald Teague; Leonard B Bacharier; Ngoc P Ly; Wanda Phipatanakul; Kristie R Ross; Joe Zein; Nizar N Jarjour Journal: J Allergy Clin Immunol Date: 2019-10-08 Impact factor: 10.793
Authors: Rodney D Britt; Michael A Thompson; Sarah Sasse; Christina M Pabelick; Anthony N Gerber; Y S Prakash Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-10-18 Impact factor: 5.464
Authors: Alvin T Kho; Michael J McGeachie; Jiang Li; Robert P Chase; Sami S Amr; Annette T Hastie; Gregory A Hawkins; Xingnan Li; Geoffrey L Chupp; Deborah A Meyers; Eugene R Bleecker; Scott T Weiss; Kelan G Tantisira Journal: Thorax Date: 2021-09-27 Impact factor: 9.102